Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Collyar: What's In It for Patients?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Nov
02
Today In Oncology
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
Current Public Knowledge Rates on Alcohol and Cancer Risks
Sacituzumab Tirumotecan Extends PFS OS in Advanced Recurrent Endometrial Cancer
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo